Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease
O'Reilly, Maeve Sanderson, Robin Wilson, William Iyengar, Sunil Lambert, Jonathan Eyre, Toby
O'Reilly, Maeve
Sanderson, Robin
Wilson, William
Iyengar, Sunil
Lambert, Jonathan
Eyre, Toby
Glos Author
Date
2022-07-27
Journal Title
Subject
Type
Journal Article
Collections
Abstract
No abstract available
Citation
O'Reilly, M. A., Sanderson, R., Wilson, W., Iyengar, S., Lambert, J., McCulloch, R., Eyre, T. A., & BSH Guidelines Committee Haemato-oncology Task Force (2022). Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. British journal of haematology, 199(1), 40–44. https://doi.org/10.1111/bjh.18378
Registration number
License
Free access to article on publisher's webpage. Click DOI.
Usage rights
Free access to article on publisher's webpage. Click DOI.